Prognostic Factors for Achievement of CR for 53 AML Patients
| Parameters . | Patients Who Achieved CR (32 patients) . | Patients Who Did Not Achieve CR (21 patients) . | P Value . |
|---|---|---|---|
| MDR parameters | |||
| Pgp (measured by flow cytometry) | 1.81 ± 0.79 | 3.01 ± 1.51 | .004 |
| Modulatory effect of CsA on calcein-AM uptake | 1.53 ± 0.34 | 1.90 ± 0.51 | .01 |
| Modulatory effect of CsA on Rh 123 uptake* | 1.51 ± 0.95 | 2.21 ± 1.12 | .02 |
| Modulatory effect of CsA on daunorubicin uptake* | 1.10 ± 0.52 | 1.98 ± 0.85 | .04 |
| MRP (measured by flow cytometry) | 1.55 ± 0.33 | 1.78 ± 0.45 | NS |
| Modulatory effect of probenecid on calcein efflux | 1.53 ± 0.25 | 1.73 ± 0.27 | .03 |
| LRP (measured by flow cytometry) | 3.54 ± 1.71 | 4.05 ± 1.66 | NS |
| Other parameters | |||
| Age (yr) | 52 ± 19 | 59 ± 19 | .05 |
| CD34+ patients (%)† | 52% | 85% | .01 |
| Unfavorable cytogenetic | 2% | 28% | .02 |
| Parameters . | Patients Who Achieved CR (32 patients) . | Patients Who Did Not Achieve CR (21 patients) . | P Value . |
|---|---|---|---|
| MDR parameters | |||
| Pgp (measured by flow cytometry) | 1.81 ± 0.79 | 3.01 ± 1.51 | .004 |
| Modulatory effect of CsA on calcein-AM uptake | 1.53 ± 0.34 | 1.90 ± 0.51 | .01 |
| Modulatory effect of CsA on Rh 123 uptake* | 1.51 ± 0.95 | 2.21 ± 1.12 | .02 |
| Modulatory effect of CsA on daunorubicin uptake* | 1.10 ± 0.52 | 1.98 ± 0.85 | .04 |
| MRP (measured by flow cytometry) | 1.55 ± 0.33 | 1.78 ± 0.45 | NS |
| Modulatory effect of probenecid on calcein efflux | 1.53 ± 0.25 | 1.73 ± 0.27 | .03 |
| LRP (measured by flow cytometry) | 3.54 ± 1.71 | 4.05 ± 1.66 | NS |
| Other parameters | |||
| Age (yr) | 52 ± 19 | 59 ± 19 | .05 |
| CD34+ patients (%)† | 52% | 85% | .01 |
| Unfavorable cytogenetic | 2% | 28% | .02 |
*Only 49 patients were tested.
Samples were considered positive for CD34 when more than 20% of viable cells were stained with CD34 antibody in excess of the negative control.